Leading the charge to develop new, targeted approaches to treat disease, Children’s Hospital of Philadelphia Research Institute investigators have uncovered more of the mechanistic underpinnings of the migratory T cell response, and CHOP announced the inaugural Patricia Brophy Endowed Chair in Neuroblastoma Research to advance innovation into less toxic treatment options for specific cancers. Out in the community, CHOP has teamed up with the Philadelphia Housing Development Corporation for the pilot program of its Healthier Together initiative, and researchers are learning how best to help survivors of violence after they are discharged from the hospital.
Tag Archive: Yael Mossé
Long before he entered medical school, John M. Maris, MD, pediatric oncologist and the recent recipient of the National Cancer Institute’s Outstanding Investigator Award, became captivated by the mysteries of neuroblastoma. A cancer of the peripheral (not brain) nervous system, neuroblastoma accounts for 7 percent of all childhood cancers and 15 percent of all childhood cancer deaths.
The end of the year has come up fast, and so have important advances in pediatric research at Children’s Hospital of Philadelphia. This week’s In the News starts off with a celebration of two remarkable patients and their dedicated pediatric oncologist.
Although October is just ending, we’re already looking ahead to the New Year in this week’s installment of In the News.
Young scientists may have passion and brilliant ideas, but unfortunately, they often do not add up to federal funding dollars. This is particularly problematic in pediatric cancer research, which receives just 4 percent of the National Cancer Institute’s $4.95 billion budget.
Our news highlights from this week cover some provocative topics in pediatric research, from serious teen violence in Philadelphia neighborhoods to head trauma injuries in student athletes across the country. Read on for details about the latest research developments and projects at The Children’s Hospital of Philadelphia.
Pediatric cancer researchers at The Children’s Hospital of Philadelphia believe they have succeeded in their search for a powerful next-generation drug for neuroblastoma tumors with mutations in the anaplastic lymphoma kinase (ALK) gene associated with the cancer.